Boehringer Ingelheim Launches the First-Ever Registered Stem Cell-Based Veterinary Medicine
Boehringer Ingelheim launches Arti-Cell® Forte in Europe for the ‘reduction of mild to moderate recurrent lameness associated with non-septic joint inflammation in horses’.
Equine lameness is truly common and impacts horse performance as well as equine welfare1 . Current treatment is not satisfactory for all cases and there is a clear need for innovation and new treatment options. Hence, the significant interest in treatment beyond symptoms, namely combatting the underlying root cause.
Arti-Cell® Forte is a groundbreaking first-ever approved therapy, developed towards targeting lameness, utilising specifically primed, chondrogenic induced stem cells. Arti-Cell® Forte comes in an ultra-low frozen ready-to-use presentation.
Boehringer Ingelheim and Global Stem cell Technology (GST), that formed a partnership last year, have the same ambition to bring new treatments and solutions to improve animal health; therefore, Arti-Cell® Forte was specifically designed for horses to provide a convenient and long-term2 solution for recurrent lameness.
“A quarter of the entire equine population1 develops osteoarthritis at some point in their life. Priming the cells towards cartilage aids them to deliver the right activities in the affected joint,” says Jan Spaas, CEO of GST. “We are absolutely delighted with our first marketing authorisation from the European Commission and the first stem cell-based product in Animal Health. We are sure that with our partner Boehringer Ingelheim this product will become a game changer in equine health.”
Dr. Erich Schoett, Head of the Global Strategic Business Unit Equine at Boehringer Ingelheim, shares: “We are proud to continue to set new standards of care for horses to optimise their health and well-being in partnership with veterinarians. Early disease detection and early treatment are key to ensure that horses are healthy and live longer, happier lives. Arti-Cell® Forte as the first-ever approved stem cell-based product offers to veterinarians and horse owners a ready-to-use solution to help raising the health and quality of life for horses with mild to moderate recurrent lameness”.
Following the scientific review by the European Medicines Agency2 and decision of EU marketing authorisation by the European Commission, Arti-Cell® Forte is now approved as a veterinary medicine for the treatment of equine lameness. It will be available from May and June 2019 onwards in a range of European Countries.
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Please click on the link for ‘Notes to Editors’ and ‘References’:
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-QUANERGY-SYSTEMS18.7.2019 21:02:06 CEST | Press release
Quanergy and Chery Established Partnership to Propel a New Era of Autonomous Vehicles and Smart Cities
LARSEN-&-TOUBRO-INFOTECH18.7.2019 18:10:08 CEST | Press release
LTI USD Revenue Growth up 11.5% YoY; Digital Revenues at 39%
NY-MOODY’S-ANALYTICS18.7.2019 17:32:06 CEST | Press release
Moody’s Analytics Wins Wholesale Modelling Software of the Year at Risk Technology Awards
FABASOFT18.7.2019 16:41:12 CEST | Press release
Fabasoft is a “Strong Performer” for Cloud Content Platforms, Q3 2019
CA-GILEAD-SCIENCES,-INC.18.7.2019 14:32:06 CEST | Press release
Gilead to Present New Data on HIV Prevention, Treatment and Cure Research at IAS 2019
BOEHRINGER-INGELHEIM18.7.2019 14:03:04 CEST | Press release
Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom